Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bronchiolitis obliterans

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Bronchiolitis obliterans. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-000499-14 Sponsor Protocol Number: P120110 Start Date*: 2013-08-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10049202 Bronchiolitis obliterans LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004171-39 Sponsor Protocol Number: INCB39110-214 Start Date*: 2020-01-10
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
    Medical condition: Bronchiolitis Obliterans Syndrome following Lung Transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10029888 Obliterative bronchiolitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022467-36 Sponsor Protocol Number: IFN_BOSZT_01 Start Date*: Information not available in EudraCT
    Sponsor Name:Freistaat Bayern
    Full Title: A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy
    Medical condition: steroid-refractory bronchiolitis obliterans
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10029888 Obliterative bronchiolitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004304-38 Sponsor Protocol Number: 12011.203 Start Date*: 2012-01-06
    Sponsor Name:PARI Pharma GmbH
    Full Title: A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy
    Medical condition: Prevention of Bronchiolitis Obliterans Syndrome in lung transplant
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003801-15 Sponsor Protocol Number: 12011.202 Start Date*: Information not available in EudraCT
    Sponsor Name:PARIPharma GmbH
    Full Title: A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A ...
    Medical condition: Bronchiolitis Obliterans Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049202 Bronchiolitis obliterans LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003800-73 Sponsor Protocol Number: 12011-201 Start Date*: 2009-07-14
    Sponsor Name:PARI Pharma GmbH
    Full Title: A phase II, multicentre, randomised, double-blind, placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aer...
    Medical condition: Prevention of bronchiolitis obliterans syndrome in lung transplant
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002987-29 Sponsor Protocol Number: BT–L-CsA–303–FU Start Date*: 2020-02-12
    Sponsor Name:Zambon SpA
    Full Title: An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed the participation to BOSTON 1 and BOSTON 2 st...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single or post Double Lung Transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003893-46 Sponsor Protocol Number: NA Start Date*: 2009-11-03
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: AZITHROMYCIN IN BRONCHIOLITIS OBLITERANS SYNDROME
    Medical condition: - Chronic rejection at 1 and 2 year post-lung transplantation - Mortality at 1 and 2 year post-lung transplantation - Acute rejection rate at 1 and 2 post-lung transplantation - Infection rate at 1...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029888 Obliterative bronchiolitis LLT
    12.0 10049202 Bronchiolitis obliterans LLT
    12.0 10068805 Follicular bronchiolitis LLT
    12.0 10019319 Heart-lung transplant rejection LLT
    12.0 10025127 Lung transplant LLT
    12.0 10050433 Prophylaxis against lung transplant rejection LLT
    12.0 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.0 10051604 Lung transplant rejection LLT
    12.0 10056409 Heart and lung transplant LLT
    12.0 10016547 FEV LLT
    12.0 10016549 FEV 1 abnormal LLT
    12.0 10016550 FEV 1 decreased LLT
    12.0 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021983-14 Sponsor Protocol Number: MLK002 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to treat BOS.
    Medical condition: -Mortality at 1 and 2 year post diagnosis of BOS -Infection rate during BOS -Evolution of pulmonary function after diagnosis of BOS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022027-30 Sponsor Protocol Number: VIT001 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to prevent BOS
    Medical condition: A study to prevent the occurence of chronic rejection after lung transplantation. Other points of investigation include lung function evolution, rate of survival, BAL cellularity, infection rate, r...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002022-12 Sponsor Protocol Number: EPOS-CT-001 Start Date*: 2015-08-06
    Sponsor Name:Clinical Trials Unit, Rigshospitalet
    Full Title: A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.
    Medical condition: Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10049202 Bronchiolitis obliterans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018724-16 Sponsor Protocol Number: AZI002 Start Date*: 2010-04-15
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: A prospective, open-label, pilot-study of azithromycin for lymphocytic bronchi(oli)tis after lung transplantation
    Medical condition: Lymphocytic airway inflammation (so-called Lymphocytic Bronchitis or Bronchiolitis) post-lung transplantation: evolution of airway inflammation (BAL, TBB), pulmonary function, radiology after 3 mon...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006414 Bronchial biopsy abnormal LLT
    12.1 10025041 Lung biopsy abnormal LLT
    12.1 10063078 Bronchoalveolar lavage abnormal LLT
    12.1 10049083 Respiratory tract infection NOS LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    12.1 10057799 Computerised tomogram thorax abnormal LLT
    12.1 10025127 Lung transplant LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.1 10066543 Acute allograft rejection LLT
    12.1 10049237 Acute cellular rejection LLT
    12.1 10039008 Reversible airways obstruction NOS LLT
    12.1 10039008 Reversible airways obstruction NOS LLT
    12.1 10068956 Respiratory tract inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003205-25 Sponsor Protocol Number: BT–L-CsA–302–DLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003331-32 Sponsor Protocol Number: AZI003 Start Date*: 2013-06-18
    Sponsor Name:KULeuven and University Hospitals Leuven
    Full Title: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTA...
    Medical condition: EARLY LUNG ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050437 Prophylaxis against heart and lung transplant rejection LLT
    14.1 10022891 - Investigations 10016547 FEV LLT
    14.1 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    14.1 10022891 - Investigations 10006414 Bronchial biopsy abnormal LLT
    14.1 10022891 - Investigations 10025041 Lung biopsy abnormal LLT
    14.1 10022891 - Investigations 10016549 FEV 1 abnormal LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    14.1 10021428 - Immune system disorders 10049237 Acute cellular rejection LLT
    14.1 10021428 - Immune system disorders 10066543 Acute allograft rejection LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039008 Reversible airways obstruction NOS LLT
    14.1 10021428 - Immune system disorders 10019319 Heart-lung transplant rejection PT
    14.1 10022891 - Investigations 10016550 FEV 1 decreased LLT
    14.1 10022891 - Investigations 10057799 Computerised tomogram thorax abnormal PT
    14.1 10022891 - Investigations 10063078 Bronchoalveolar lavage abnormal PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068956 Respiratory tract inflammation PT
    14.1 100000004862 10049083 Respiratory tract infection NOS LLT
    14.1 10022891 - Investigations 10016553 FEV 1 low LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003204-39 Sponsor Protocol Number: BT–L-CsA–301–SLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001747-31 Sponsor Protocol Number: P160907 Start Date*: 2019-04-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Tranplant (LTx) recipients with bronchiolitis obliterans sydrome (BOS) grade 1-2
    Medical condition: Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10029888 Obliterative bronchiolitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000718-13 Sponsor Protocol Number: BT–L-CsA–201–SCT Start Date*: 2019-12-17
    Sponsor Name:Zambon SpA
    Full Title: BOSTON-4: A Phase IIa Multi-Center, Randomized, Single-Blind Safety and Tolerability Study of inhaled Liposomal Cyclosporine A in Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoieti...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001290-25 Sponsor Protocol Number: CERL080A2415 Start Date*: 2005-09-14
    Sponsor Name:St Vincent's Hospital
    Full Title: A 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing de Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclospori...
    Medical condition: Heart-Lung, bilateral lung and single lung transplant recipients ICD Classification: K01-K01.9, E53.9+Z94.1, E53.9+Z94.2, E53.9+Z94.3
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000485-36 Sponsor Protocol Number: G0500705 Start Date*: 2006-08-23
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation
    Medical condition: Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001945-32 Sponsor Protocol Number: knoop1 Start Date*: 2006-11-13
    Sponsor Name:ULB Erasme
    Full Title: Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.
    Medical condition: Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:09:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA